期刊文献+

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease 被引量:3

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease
下载PDF
导出
摘要 Parkinson's disease (PD) is the most common motor neurode- generative disorder affecting approximately 4 million people worldwide. Although PD presents primarily with motor dysfunction, non-motor symptoms including cognitive decline, mood disorders, reduced olfaction and constipation are also of- ten present, with some of these non-motor symptoms even pre- senting prior to the onset of motor symptoms. It is well known that PD is largely caused by the gradual degeneration of dopa- minergic neurons within the substantia nigra pars compacta (SNc), along with the presence of protein aggregates called Lewy bodies, which consist primarily of ct-synuclein and are found in the cytoplasm of surviving neurons. This ongoing cell loss and Lewy body pathology is not confined to the SNc, but is also seen in other brain regions implicated in PD pathogenesis such as the locus ceruleus. Parkinson's disease (PD) is the most common motor neurode- generative disorder affecting approximately 4 million people worldwide. Although PD presents primarily with motor dysfunction, non-motor symptoms including cognitive decline, mood disorders, reduced olfaction and constipation are also of- ten present, with some of these non-motor symptoms even pre- senting prior to the onset of motor symptoms. It is well known that PD is largely caused by the gradual degeneration of dopa- minergic neurons within the substantia nigra pars compacta (SNc), along with the presence of protein aggregates called Lewy bodies, which consist primarily of ct-synuclein and are found in the cytoplasm of surviving neurons. This ongoing cell loss and Lewy body pathology is not confined to the SNc, but is also seen in other brain regions implicated in PD pathogenesis such as the locus ceruleus.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2015年第9期1403-1405,共3页 中国神经再生研究(英文版)
基金 in part has been supported by the Neurosurgical Research Foundation, South Australia, Australia
  • 相关文献

参考文献11

  • 1Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192.
  • 2Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacal Rev 57:173-185.
  • 3Kortekaas R, Leenders KL, van Oostrom Ie, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann NeuroI57:176-179.
  • 4Liu CQ, Chen Z, Liu FX, Hu DN, Luo IH (2007) Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6- hydroxydopamine-Iesioned rats. Neuropharmacology 53:832-841.
  • 5Pisani V, Stefani A, Pierantozzi M, Natoli S, Stanzione P, Franciotta D, Pisani A (2012) Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation 9:188.
  • 6Rite I, Machado A, Cano I, Venero JL (2007) Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. I Neurochern 101:1567-1582.
  • 7Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 7:e34138.
  • 8Thornton E, Tran TT, Vink R (2010) A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 481:64- 67.
  • 9Thornton E, Hassall MM, Corrigan F, Vink R (2014) The NKI receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a herni-parkinsonian rodent model. Parkinsonism Relat Disord 20:508-513.
  • 10Westin IE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 26:9448-9461.

同被引文献22

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部